Lv1
28 积分 2024-03-11 加入
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
4小时前
已完结
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
1个月前
已完结
Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer
3个月前
已完结
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
5个月前
已完结
Global patterns and trends in breast cancer incidence and mortality across 185 countries
8个月前
已完结
Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial
9个月前
已完结
Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report
11个月前
已完结
Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor penetration
1年前
已完结
Bystander effect of antibody–drug conjugates: fact or fiction?
1年前
已完结
皖公网安备34019202002308
